Discussion
Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…